Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming E...
October 16 2018 - 7:30AM
Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage
biopharmaceutical company developing novel oncology therapeutics,
announced today that clinical data from its SL-701 and SL-801
trials have been selected for presentation, including an oral
presentation, at the upcoming European Society of Medical Oncology
(ESMO) Annual Congress 2018 to be held from October 19-23, in
Munich, Germany. The details of the data presentations are outlined
below.
Results of Phase II Trial Of SL-701, a Novel
Immunotherapy Targeting IL-13Ra2, Epha2, and Survivin, in Adults
with Second-Line Recurrent Glioblastoma (GBM)
- Type: Oral Presentation
- Session: Proffered Paper session – CNS tumours
- Presentation Number: 373O
- Date: Friday, October 19, 2018
- Lecture Time: 16:39 – 16:51 CEST (10:39 AM EDT)
- Speaker: David Peereboom, MD; Cleveland Clinic
Interim Results from a Phase 1 Trial of SL-801, a Novel
XPO-1 Inhibitor, in Patients with Advanced Solid
Tumors
- Type: Poster Presentation
- Session: Poster display session: Breast cancer - early stage,
locally advanced & metastatic, CNS tumours, Developmental
therapeutics, Genitourinary tumours - prostate & non-prostate,
Palliative care, Psycho-oncology, Public health policy, Sarcoma,
Supportive care
- Presentation Number: 428P
- Date: Monday, October 22, 2018
- Time: 12:45 – 13:45 CEST (6:45 – 7:45 AM EDT)
- Speaker: Todd M. Bauer, MD; Tennessee Oncology
Abstracts are currently available on the ESMO congress website
(www.esmo.org). Following each presentation at the conference, the
data presented will be available on Stemline’s website
(www.stemline.com) under the Scientific Presentations tab.
About BPDCNPlease visit the BPDCN disease
awareness website: www.bpdcninfo.com.
About Stemline TherapeuticsStemline
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing novel oncology therapeutics. Stemline is developing
three clinical stage product candidates, ELZONRISTM (tagraxofusp;
SL-401), SL-801, and SL-701. ELZONRIS is a targeted therapy
directed to the interleukin-3 receptor (CD123) present on a range
of malignancies. ELZONRIS has completed a pivotal trial in blastic
plasmacytoid dendritic cell neoplasm (BPDCN), for which it was
granted breakthrough therapy designation (BTD). The pivotal trial
met its primary endpoint, and a Biologics License Application (BLA)
has been accepted for filing and granted Priority Review by the
FDA. ELZONRIS is also being evaluated in clinical trials in
additional indications including chronic myelomonocytic leukemia
(CMML), myelofibrosis (MF), and others. SL-801 is a novel oral
small molecule reversible inhibitor of XPO1 that is currently in a
Phase 1 trial of patients with advanced solid tumors; dose
escalation is ongoing. SL-701, an immunotherapeutic, has completed
a Phase 2 trial in patients with second-line glioblastoma; data and
next steps for the program are being evaluated.
Forward-Looking StatementsSome of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our BLA submission to the FDA; the success and timing of our
clinical trials and preclinical studies for our product candidates,
including site initiation, institutional review board approval,
scientific review committee approval, patient accrual, safety,
tolerability and efficacy data observed, and input from regulatory
authorities including the risk that the FDA or other ex-U.S.
national drug authority ultimately does not agree with our data,
find our data supportive of approval, or approve any of our product
candidates; our plans to develop and commercialize our product
candidates; market acceptance of our products; reimbursement
available for our products; our available cash and investments; our
ability to obtain and maintain intellectual property protection for
our product candidates; our ability to obtain and maintain
intellectual property protection for our product candidates; our
ability to manufacture; the performance of third-party
manufacturers, clinical research organizations, clinical trial
sponsors and clinical trial investigators; and other risk factors
identified from time to time in our reports filed with the SEC. Any
forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
ContactInvestor RelationsStemline Therapeutics,
Inc.750 Lexington AvenueEleventh FloorNew York, NY 10022Tel:
646-502-2307Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024